Uncategorized

Novant Health Initiates Phase 2b/3 Trial with CytoDyn’s (OTC: CYDY) Leronlimab for Severely and Critically Ill COVID-19 Patients

FDA has approved 54 Emergency INDs to allow access to leronlimab for severely and critically ill COVID-19 patients VANCOUVER, Washington and WINSTON-SALEM, May 07, 2020  — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a […]

Uncategorized

CytoDyn’s (OTC: CYDY) Phase 2 Basket Trial for 22 Solid Cancer Tumors Treats First Patient with Leronlimab; Patient Enrollment Delayed Due to COVID-19

VANCOUVER, Washington, April 15, 2020  — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it has […]

Uncategorized

CytoDyn Signs Letter of Intent for the Joint Development and Licensing of Leronlimab in China with Longen China Group

VANCOUVER, Washington, Feb 12, 2020 (GLOBE NEWSWIRE via COMTEX) — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, […]

Uncategorized

Next Super Stock Investor Conference September 26, 2019

September 26, 2019 conference presenters:     Hoth Therapeutics, Inc. (NASDAQ: HOTH) CEO Robb Knie, shares the latest updates on Hoth’s pipeline of targeted dermatological therapies, which address multi-billion dollar market opportunities, including: eczema, psoriasis, chronic wound […]

Uncategorized

Nightfood (OTC: NGTF) Schedules Fourth Ice Cream Production Run for June; Product of the Year Winner Building Inventory in Advance of Major Partnership Announcement

Tarrytown, NY, May 01, 2019  — Nightfood, Inc. (OTCQB:NGTF), the innovative ice cream company solving America’s $50 billion-dollar nighttime snacking problem, announced today that the company has scheduled a fourth ice cream production run for […]